Mentoring in HIV and Tuberculosis Research

艾滋病毒和结核病研究的指导

基本信息

项目摘要

DESCRIPTION (provided by applicant): Timothy R. Sterling, M.D. is on the Physician-Scientist (tenure) track at Vanderbilt University Medical Center, with 80% effort dedicated to research. He seeks funding for the K24 Mid-Career Investigator Award to expand his patient-oriented research program in HIV and tuberculosis, and to mentor clinical investigators in these areas. Dr. Sterling has consistently demonstrated a commitment to epidemiological and translational research in HIV and tuberculosis, and has mentored 20 young investigators to date. His trainees have been very successful in publishing their work, and almost all have remained in academic medicine. The environment at Vanderbilt is extremely conducive to training clinical investigators, with an active General Clinical Research Center, degree programs in Masters in Public Health and Masters of Science in Clinical Investigation (both supported by a NIH K30 award), a Mentored Clinical Research Scholar Program (K12) and several training grants (T32), including infectious diseases, pulmonary, and health services research. There are also several training programs dedicated to women and under-represented minorities. Dr. Sterling has a comprehensive mentoring plan that focuses on ethical conduct of research, formulation of a scientific question, study design, study conduct, manuscript preparation, grant writing, time management, oral presentations, potential conflicts of interest, establishment of a national reputation and establishment of independence. Dr. Sterling's research is focused on the following areas: 1) outcomes of HIV infection that influence timing of antiretroviral therapy initiation; 2) immunogenetic risk factors for tuberculosis infection and disease; 3) novel strategies to treat M. tuberculosis infection and disease; and 4) optimizing effectiveness of treatment of tuberculosis in HIV-infected persons. Future research will also focus on fluoroquinolone resistance in M. tuberculosis, and its possible association with HIV infection. Given the tremendous global burden of HIV and tuberculosis, highly-skilled investigators are needed to guide and improve treatment of both diseases. Due to the disproportionate impact that these diseases have had on women and persons of color, investigators from these demographic groups are particularly needed. The K24 award will allow Dr. Sterling to continue to pursue his highly-productive career in patient-oriented research in HIV and tuberculosis, and mentor the next generation of researchers to do the same.
描述(由申请人提供):蒂莫西·R·斯特林(Timothy R. Sterling),医学博士(M.D.他寻求为K24中级研究员奖的资金,以扩大其面向患者的艾滋病毒和结核病研究计划,并在这些领域指导临床研究人员。斯特林博士一直表现出对艾滋病毒和结核病流行病学和转化研究的承诺,并指导了20名年轻的研究者。他的学员在出版工作方面非常成功,几乎所有人都一直在学术医学上。范德比尔特(Vanderbilt)的环境极为有利于培训临床研究人员,一个活跃的一般临床研究中心,公共卫生硕士学位和临床研究科学硕士学位课程(均得到NIH K30奖的支持),一项受过指导的临床研究学者计划(K12)(K12)和几项培训格兰特(K12)和包括感染性疾病疾病(T32),包括感染性疾病,肺部,肺部,健康服务。还有一些专门针对妇女和代表性不足的少数民族的培训计划。斯特林博士制定了一项全面的指导计划,侧重于研究的道德行为,一项科学问题,研究设计,研究行为,手稿准备,赠款写作,时间管理,口头陈述,潜在的利益冲突,建立民族声誉和独立建立。 Sterling博士的研究重点是以下领域:1)影响抗逆转录病毒疗法开始的HIV感染结果; 2)结核病感染和疾病的免疫遗传危险因素; 3)治疗结核分枝杆菌感染和疾病的新型策略; 4)优化对艾滋病毒感染者的结核病治疗的有效性。未来的研究还将集中在结核分枝杆菌中的氟喹诺酮耐药性及其与HIV感染的可能关联。鉴于全球艾滋病毒和结核病的巨大负担,需要高技能的研究人员来指导和改善两种疾病的治疗。由于这些疾病对妇女和有色人种的影响不成比例的影响,因此特别需要这些人口组的研究人员。 K24奖将使Sterling博士继续从事他在艾滋病毒和结核病方面的患者研究方面的生产率,并指导下一代研究人员做同样的事情。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)

暂无数据

数据更新时间:2024-06-01

TIMOTHY R STERLING的其他基金

Fluoroquinolone Resistance in M. Tuberculosis
结核分枝杆菌对氟喹诺酮类药物的耐药性
  • 批准号:
    7094514
    7094514
  • 财政年份:
    2006
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Fluoroquinolone Resistance in M. Tuberculosis
结核分枝杆菌对氟喹诺酮类药物的耐药性
  • 批准号:
    7580949
    7580949
  • 财政年份:
    2006
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Fluoroquinolone Resistance in M. Tuberculosis
结核分枝杆菌对氟喹诺酮类药物的耐药性
  • 批准号:
    7367845
    7367845
  • 财政年份:
    2006
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Fluoroquinolone Resistance in M. Tuberculosis
结核分枝杆菌对氟喹诺酮类药物的耐药性
  • 批准号:
    7183481
    7183481
  • 财政年份:
    2006
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Fluoroquinolone Resistance in M. Tuberculosis
结核分枝杆菌对氟喹诺酮类药物的耐药性
  • 批准号:
    7769894
    7769894
  • 财政年份:
    2006
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Mentoring in HIV and Tuberculosis Research
艾滋病毒和结核病研究的指导
  • 批准号:
    8645585
    8645585
  • 财政年份:
    2005
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Mentoring in HIV and Tuberculosis Research
艾滋病毒和结核病研究的指导
  • 批准号:
    7227425
    7227425
  • 财政年份:
    2005
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Mentoring in HIV and Tuberculosis Research
艾滋病毒和结核病研究的指导
  • 批准号:
    7413396
    7413396
  • 财政年份:
    2005
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Mentoring in HIV and Tuberculosis Research
艾滋病毒和结核病研究的指导
  • 批准号:
    8042550
    8042550
  • 财政年份:
    2005
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Mentoring in HIV and Tuberculosis Research
艾滋病毒和结核病研究的指导
  • 批准号:
    8277987
    8277987
  • 财政年份:
    2005
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:

相似国自然基金

Rv3737促进M2型巨噬细胞极化在结核分枝杆菌感染中的作用及机制研究
  • 批准号:
    82360002
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
工程化CRISPR蛋白增强核酸检测灵敏度及耦合微流控技术实现高通量结核分枝杆菌耐药检测的研究
  • 批准号:
    82300128
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
结核分枝杆菌游离DNA谱驱动的CRISPR技术快速诊断结核病及其疗效监测研究
  • 批准号:
    82302614
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
结核分枝杆菌遗传异质性对结核病复发的影响及机制研究
  • 批准号:
    82373650
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
基于图形泛基因组的中国结核分枝杆菌高质量参考基因组的构建研究
  • 批准号:
    82373649
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目

相似海外基金

The human lung and lung-draining lymph node response to Mycobacterium tuberculosis
人肺和肺引流淋巴结对结核分枝杆菌的反应
  • 批准号:
    10666017
    10666017
  • 财政年份:
    2023
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Role of LRRK2 in immunity in a nonhuman primate model of SIV
LRRK2 在 SIV 非人灵长类动物模型免疫中的作用
  • 批准号:
    10693552
    10693552
  • 财政年份:
    2023
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA)
结核分枝杆菌 (MTB) 质量评估计划 (TBQA)
  • 批准号:
    10788125
    10788125
  • 财政年份:
    2023
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Identifying CMV Retinitis as a Reversible Cause of Vision Loss in Persons with HIV-associated Meningitis
确定 CMV 视网膜炎是 HIV 相关脑膜炎患者视力丧失的可逆原因
  • 批准号:
    10752843
    10752843
  • 财政年份:
    2023
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别:
Mathematical modeling of Mycobacterium tuberculosis dissemination
结核分枝杆菌传播的数学模型
  • 批准号:
    10364119
    10364119
  • 财政年份:
    2022
  • 资助金额:
    $ 16.16万
    $ 16.16万
  • 项目类别: